Literature DB >> 4280522

Inhibition of aldosterone production in diuretic-induced hyperaldosteronism by aldosterone antagonist canrenone in man.

H C Erbler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4280522     DOI: 10.1007/bf00501467

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  7 in total

1.  [THIN-LAYER CHROMATOGRAPHIC STUDIES OF 3'-(3-OXO-7-ALPHA-ACETYLTHIO-17-BETA-HYDROXY-4-ANDROSTEN-17-ALPHA-YL)-PROPIONIC ACID GAMMA-LACTONE AND ITS METABOLITES IN MAN].

Authors:  L ZICHA; F WEIST; E SCHMID
Journal:  Arzneimittelforschung       Date:  1964-06

2.  Stimulation of aldosterone production in vitro and its inhibition by spironolactone.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

3.  On the mechanism of the inhibitory action of the spirolactone SC 9376 (aldadiene) on the production of corticosteroids in rat adrenals in vitro.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

4.  Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

Authors:  W Sadée; M Dagcioglu; R Schröder
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

5.  [Aldadiene and other metabolites in the blood and urine after rectal appliacation of spironolactone and injection of aldaliene-potassium].

Authors:  H Wagner; F Weist; L Zicha
Journal:  Arzneimittelforschung       Date:  1967-04

6.  A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma.

Authors:  N GOCHMAN; C L GANTT
Journal:  J Pharmacol Exp Ther       Date:  1962-03       Impact factor: 4.030

7.  Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone).

Authors:  A Karim; E A Brown
Journal:  Steroids       Date:  1972-07       Impact factor: 2.668

  7 in total
  5 in total

1.  Canrenoate disposition in dogs. Tissue distribution and elimination.

Authors:  J Kuhlmann; V Kötter; N Rietbrock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-06       Impact factor: 3.000

2.  Interference of spironolactone therapy with adrenal steroid metabolism in secondary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; M Schöneshöfer; M L'age; W Oelkers
Journal:  Klin Wochenschr       Date:  1978-04-01

3.  Influence of spironolactone on serum corticosteroids in primary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; W Oelkers
Journal:  Klin Wochenschr       Date:  1979-02-15

4.  Effect of aldosterone antagonist canrenone on plasma aldosterone concentration and plasma renin activity, and on the excretion of aldosterone and electrolytes by man.

Authors:  H C Erbler; H Wernze; M Hilfenhaus
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

5.  Spironolactone in thiazide-induced hypokalaemia: variable response between patients.

Authors:  L E Ramsay; J Hettiarachchi
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.